Secretary Kennedy Announces New Appointments to U.S. Preventive Services Task Force

• by Assistant Secretary for Public Affairs (ASPA)

• September 17, 2026

FDA revises monitoring for SCLC therapy

Initial monitoring decreases from 22 to 24 hours to 6 to 8 hours from the start of the first 2 infusions.

• by Kathryn Wighton

• September 15, 2026

• 2 min

Tirzepatide’s cardiovascular effects in clinical practice

Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

• by Kathryn Wighton

• August 28, 2026

• 4 min

Microsporidial keratoconjunctivitis may mimic allergy

Molecular testing identified Encephalitozoon hellem in a 9-year-old orthokeratology lens wearer after conventional treatment failed.

• by Andrea Surnit

• September 16, 2026

• 4 min